Skip to content

Decoding the Hallmark Features of Modular CAR Domains and Their Impact on CAR T Cell Tumoricidal Activity 2305603

Jul 2026 · Journal of Immunology · Vol 215 · 0 citations

TL;DR

A model is created to establish the role of each domain and how they interact to propagate an activation signal, recruit a unique signalosome, and dictate the phenotype and function of CAR T cells.

Abstract

Engineering T cells to express a Chimeric Antigen Receptor (CAR) directs potent tumor cytotoxicity, and this cellular immunotherapy has yielded robust success in hematological malignancies. However, in solid tumor models, including neuroblastoma, regression after CAR administration is only transient. The linked domains of CARs determine their activation threshold and can be optimized to overcome efficacy barriers, including exhaustion, persistence, and activation threshold. Yet, as to how each modular domain and its variants influence T cell phenotype and function is poorly understood. We generated a library of 12 constructs that combinatorially link 3 distinct hinge regions (CD8, CD28, or IgG), 2 transmembrane domains (CD8 or CD28), and 2 co-stimulatory regions (41BB or CD28), all frequently used in FDA-approved CARs. We used a scFv targeting the oncofetal antigen GPC2, an antigen with moderate to low expression in neuroblastoma. Expressing these unique CARs in human T cells, we will evaluate differences in T cell cytokine production, killing capacity, phenotype, and persistence using preclinical models of neuroblastoma. These assays will generate a high-dimensional dataset, and we will employ machine learning to identify an in vitro biosignature of CAR T cells that predicts in vivo CAR T cell killing, as well as a favorable phenotype for persistence and effector qualities. Preliminary results identified a broad range of CAR T cell cytotoxicity against neuroblastoma lines in vitro, with the transmembrane domain driving the greatest variation in killing, as well as significant interaction effects between domains. Overall, we aim to create a model to establish the role of each domain and how they interact to propagate an activation signal, recruit a unique signalosome, and dictate the phenotype and function of CAR T cells. NCI Intramural Research Program Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)

View source

Similar papers

Aug 2026

Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC.

A humanized CD70-targeted CAR-T cell therapy is developed, A174-hu1-CAR-T, with reduced fratricide and potent antitumor activity, providing a preclinical foundation to support further translational development.

Meng-Jia Zhang, Zhi-Hao Wang, Cheng Gao et al. · 1 citation
Open access Sep 2026

Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia

This study identified TIGIT KO as a potent enhancer of AdCAR-T-cell function and supports ICR gene disruption as a promising approach to improve therapeutic efficacy while reducing the systemic toxicities commonly associated with ICI therapy.

Anna-Sophia Mast, D. Atar, Lara Ruoff et al. · 0 citations
Open access Sep 2026

83 Preclinical Evaluation of LNK001: Stringent AND-Gate Fidelity and Potent Efficacy of a Dual-Antigen CAIX/ENPP3 CAR T Cell Therapy for Clear Cell Renal Cell Carcinoma

The Logic-gated INtracellular networK (LINK) platform, a Boolean AND-gate architecture in which two synthetic receptors are coupled to distinct proximal T cell signaling adapters, is developed, and LNK001, the first clinical candidate from the LINK platform, is the first clinical candidate from the LINK platform.

M. Wallet, R. Larson, Yogin Patel et al. · 0 citations
Open access Aug 2026

AI supported in silico screening of chimeric antigen receptor therapy targets

Chimeric antigen receptor (CAR) cell therapy has achieved transformative clinical success through targeting of CD19 in refractory B cell malignancies, but extension of this strategy to solid tumors, other hematological malignancies, and autoimmune disease has exposed the complexity of target selection. Antigen abundanc...

Giorgia Moranzoni, Lasse Vedel Jørgensen, Javier Herranz del Cerro et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.